Brokerages Expect Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Will Announce Earnings of -$0.60 Per Share

Equities research analysts forecast that Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) will report earnings per share (EPS) of ($0.60) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Y-mAbs Therapeutics’ earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.53). Y-mAbs Therapeutics posted earnings per share of ($0.82) during the same quarter last year, which suggests a positive year over year growth rate of 26.8%. The company is scheduled to announce its next earnings report on Thursday, November 4th.

On average, analysts expect that Y-mAbs Therapeutics will report full-year earnings of ($1.05) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to ($0.78). For the next financial year, analysts forecast that the company will report earnings of ($0.75) per share, with EPS estimates ranging from ($1.48) to ($0.17). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Y-mAbs Therapeutics.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Thursday, August 5th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.15. The business had revenue of $10.95 million during the quarter, compared to analyst estimates of $7.66 million.

A number of research firms recently commented on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $68.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 14th. Zacks Investment Research upgraded Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 12th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $54.13.

In other news, CMO Vignesh Rajah bought 1,374 shares of the firm’s stock in a transaction that occurred on Thursday, August 12th. The shares were purchased at an average price of $29.95 per share, with a total value of $41,151.30. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Thomas Gad sold 4,000 shares of the company’s stock in a transaction dated Tuesday, July 20th. The stock was sold at an average price of $32.47, for a total value of $129,880.00. The disclosure for this sale can be found here. Insiders have sold 113,221 shares of company stock worth $3,636,193 in the last three months. 27.28% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC lifted its holdings in shares of Y-mAbs Therapeutics by 2.8% in the 1st quarter. Virtus ETF Advisers LLC now owns 11,993 shares of the company’s stock valued at $363,000 after buying an additional 331 shares during the period. Sei Investments Co. lifted its holdings in shares of Y-mAbs Therapeutics by 4.5% in the 2nd quarter. Sei Investments Co. now owns 19,951 shares of the company’s stock valued at $674,000 after buying an additional 850 shares during the period. Credit Suisse AG increased its stake in Y-mAbs Therapeutics by 5.8% in the 2nd quarter. Credit Suisse AG now owns 15,567 shares of the company’s stock valued at $527,000 after purchasing an additional 851 shares in the last quarter. CNA Financial Corp increased its stake in Y-mAbs Therapeutics by 7.4% in the 2nd quarter. CNA Financial Corp now owns 13,290 shares of the company’s stock valued at $449,000 after purchasing an additional 910 shares in the last quarter. Finally, HighMark Wealth Management LLC increased its stake in Y-mAbs Therapeutics by 265.0% in the 2nd quarter. HighMark Wealth Management LLC now owns 1,281 shares of the company’s stock valued at $43,000 after purchasing an additional 930 shares in the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.

Shares of Y-mAbs Therapeutics stock traded down $0.40 on Thursday, reaching $29.15. 1,716 shares of the stock were exchanged, compared to its average volume of 267,081. Y-mAbs Therapeutics has a twelve month low of $24.77 and a twelve month high of $55.22. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -27.11 and a beta of 1.18. The business has a 50 day moving average price of $31.52 and a two-hundred day moving average price of $32.09.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Recommended Story: Why is the conference call important?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.